Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06225050 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

M-2018-334 in Hematological Malignancies

Study acronym: HAPLO2022
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of Feb 28, 2026 to Aug 21, 2026 · Study sites: 0 to 1v5 Show 2 more changesShow less
    • Start date changed from estimate of Feb 28, 2026 to Aug 21, 2026
    • Study sites: 0 to 1
  2. Start date: Oct 31, 2025 to Feb 28, 2026 Primary and study completion dates: Oct 31, 2028 to Feb 28, 2029v4 Show 1 more changeShow less
    • Primary and study completion dates: Oct 31, 2028 to Feb 28, 2029
  3. Primary and study completion dates: Apr 30, 2027 to Oct 31, 2028 Start date: Apr 30, 2024 to Oct 31, 2025v3 Show 1 more changeShow less
    • Start date: Apr 30, 2024 to Oct 31, 2025
  4. Re-verified, no change to tracked fieldsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single-center, open-label, single-arm, pilot clinical study using TCRα/β and CD45RA depleted stem cell grafts from haploidentical donors for hematopoietic cell transplantation in 12 to 18 adult patients.
Trial Details
NCT Number NCT06225050
Lead Sponsor Miltenyi Biomedicine GmbH
Collaborators: City of Hope Medical Center
Conditions Hematological Malignancies
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov